"Continue to Expect Increased Uptake of Vonjo" - Needham & Company Reiterates Buy Rating on CTI BioPharma (CTIC) with $8 Price Target
Tweet Send to a Friend
Needham & Company analyst Gil Blum reiterated a Buy rating and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
